# Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

> **NCT01671774** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 29 (actual)

## Conditions studied

- CLDN18.2-positive Gastric Adenocarcinoma
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- CLDN18.2-positive Adenocarcinoma of Esophagus

## Interventions

- **DRUG:** IMAB362
- **DRUG:** Zoledronic acid
- **DRUG:** Interleukin-2 (1 million IU)
- **DRUG:** Interleukin-2 (3 million IU)

## Key facts

- **NCT ID:** NCT01671774
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-16
- **Primary completion:** 2014-10-13
- **Final completion:** 2014-10-13
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01671774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01671774, "Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01671774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*